Results 161 to 170 of about 1,551 (185)
Some of the next articles are maybe not open access.
Clinical Pharmacokinetics, 2023
Givosiran, approved for the treatment of acute hepatic porphyria (AHP), is the first subcutaneously administered RNAi therapeutic. This analysis was undertaken to describe the plasma pharmacokinetics (PK) of givosiran and its active metabolite, AS(N-1)3' givosiran, and to identify factors that contribute to intersubject PK variability.A population PK ...
Megan, Melch +3 more
openaire +2 more sources
Givosiran, approved for the treatment of acute hepatic porphyria (AHP), is the first subcutaneously administered RNAi therapeutic. This analysis was undertaken to describe the plasma pharmacokinetics (PK) of givosiran and its active metabolite, AS(N-1)3' givosiran, and to identify factors that contribute to intersubject PK variability.A population PK ...
Megan, Melch +3 more
openaire +2 more sources
Givosiran als neue therapeutische Option
Gastro-News, 2021Heiner Wedemeyer +2 more
openaire +1 more source
Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported
Clinical Pharmacology & Therapeutics, 2022Bins, Sander +2 more
openaire +2 more sources
Acute intermittent porphyria: acute flare-up resolved with givosiran
Medicina Clínica (English Edition), 2023Andrea María, Balado González +2 more
openaire +2 more sources